CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy

Jan 12, 2018

Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy.
Read more >>

Nyheter och rapporter

January 29 2019 Lund Aktiedagen 11 December, 2018
June 3-6 2019 BIO International Convention 10 December, 2018
September 10 2019 Stockholm Aktiedagen 9 December, 2018
November 4 2019 Göteborg Stora Aktiedagen 8 December, 2018
Merab Kokaia’s lecture “Is Gene Therapy the Future Form of Treatment for Epilepsy?” very warmly received 7 December, 2018
Interim Report January – September 2018 14 November, 2018
CombiGene’s rights issue registered – BTU converted to shares and warrants 19 October, 2018
CombiGene: Warrants commence trading 19 October, 2018
Extraordinary General Meeting of shareholders in CombiGene AB (publ) 2018 18 October, 2018
Ingeneious #4 2018, News from CombiGene 11 October, 2018
5-6 November 2018 BIO Europe 10 October, 2018
20 November 2018 Gene therapy: the future treatment for epilepsy? 10 October, 2018
22-24 October 2018 2nd Annual Gene therapy for Rare Disorders Europe 10 October, 2018
International participation 9 October, 2018
Clarification of information concerning new issue 1 October, 2018
CombiGene closer to clinical trials after oversubscribed issue 27 September, 2018
Disclosure notice 25 September, 2018
CombiGene’s preference issue, amounting to 31 million kronor, oversubscribed 21 September, 2018
Jan Nilsson tell us about the future among other things in an interview with Finwire 6 September, 2018
FoU chefen Karin Agerman och VD Jan Nilsson intervjuas i samband med BioStock Live kapitalmarknadsdag 5 September, 2018

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"